SOLBRI
DEAD

Serial Number

85317171

Owner

VALEANT INTERNATIONAL BERMUDA

Attorney

Christopher L. Graff

Filing Date

May 10, 2011

Add to watchlist:

No watchlists yet
View on USPTO

SOLBRI Trademark

Serial Number: 85317171

SOLBRI is a trademark filed by VALEANT INTERNATIONAL BERMUDA on May 10, 2011. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

VALEANT INTERNATIONAL BERMUDA (64 trademarks)

NEW VENTURE HOUSE
PEMBROKE HM05 , BM

Entity Type: 03

VALEANT INTERNATIONAL (BARBADOS) SRL (69 trademarks)

WELCHES
CHRIST CHURCH BB17154 , BB

Entity Type: 99

Trademark Details

Filing Date

May 10, 2011

Registration Date

Not Registered

Published for Opposition

May 6, 2014

Goods & Services

Pharmaceutical preparations and substances for the treatment of skin disorders, diseases, conditions and ailments; pharmaceutical preparations and products for use in dermatology; antifungal preparations; pharmaceutical preparations and substances for the treatment of eye disorders, diseases, conditions and ailments; pharmaceutical preparations and products for ophthalmological use; pharmaceutical preparations and substances for the treatment of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations and substances for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations and substances for use in chemotherapy; pharmaceutical preparations and substances for use in urology; pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, anti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances for the treatment of fungal infections, onychomycosis, tinea infections, and similar diseases of the skin and nails; pharmaceutical preparations and substances for use in dermatological conditions

Filing History

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Apr 16, 2025 ASCK
ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Aug 1, 2016 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Aug 1, 2016 ABN6
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 3, 2016 TCCA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 20, 2016 EXRA
SOU EXTENSION 3 GRANTED
Jan 19, 2016 EX3G
SOU EXTENSION 3 FILED
Dec 21, 2015 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 21, 2015 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 14, 2015 EXRA
SOU EXTENSION 2 GRANTED
Jul 11, 2015 EX2G
SOU EXTENSION 2 FILED
Jun 29, 2015 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 29, 2015 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 19, 2015 EXRA
SOU EXTENSION 1 GRANTED
Feb 18, 2015 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 12, 2015 AITU
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jan 21, 2015 ASCK
SOU EXTENSION 1 FILED
Dec 18, 2014 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 18, 2014 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 1, 2014 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 6, 2014 NPUB
PUBLISHED FOR OPPOSITION
May 6, 2014 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 16, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 1, 2014 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 1, 2014 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 13, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 12, 2014 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 12, 2014 ERFR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 22, 2014 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 22, 2014 REAP
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 30, 2013 GNFN
FINAL REFUSAL E-MAILED
Sep 30, 2013 GNFR
FINAL REFUSAL WRITTEN
Sep 30, 2013 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 12, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 12, 2013 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 11, 2013 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 18, 2013 GNRN
NON-FINAL ACTION E-MAILED
Mar 18, 2013 GNRT
NON-FINAL ACTION WRITTEN
Mar 18, 2013 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 7, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 7, 2013 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Feb 27, 2013 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Aug 28, 2012 GNS2
INQUIRY TO SUSPENSION E-MAILED
Aug 28, 2012 GNSI
SUSPENSION INQUIRY WRITTEN
Aug 28, 2012 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Aug 27, 2012 RCCK
ASSIGNED TO LIE
Aug 27, 2012 ALIE
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Aug 1, 2012 ASCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 24, 2012 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 24, 2012 GNSL
SUSPENSION LETTER WRITTEN
Feb 24, 2012 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 23, 2012 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 23, 2012 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 23, 2012 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 24, 2011 GNRN
NON-FINAL ACTION E-MAILED
Aug 24, 2011 GNRT
NON-FINAL ACTION WRITTEN
Aug 24, 2011 CNRT
ASSIGNED TO EXAMINER
Aug 24, 2011 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 16, 2011 NWOS
NEW APPLICATION ENTERED
May 13, 2011 NWAP